| Name | Title | Contact Details |
|---|
MVPindex is the professional sports industry’s first index measuring athletes, teams and leagues social media brand value in real-time. What's the top tweet in all of sports? What is your top performing tweet, post or Instagram? What are the top posts from your athletes? MVPindex provides that data so you can monitor the best performing campaigns, track what the competition is doing, and create more impactful campaigns in the future. In addition, justifying which athletes to utilize for an endorsement is made easier with MVPindex. Now you can see where these athletes are ranked in comparison to one another - by sport or across multiple sports.
This page is not monitored 24 hours a day. If this is an emergency, call 9-1-1. If you need to contact the non-emergency line, call 386-313-4911. The Flagler County Sheriff’s Office reserves the right to remove the following types of comments: comm...
Umc Global Inc is a Woodinville, WA-based company in the Business Services sector.
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN